Clinical Trial

Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

Study acronym: SUMA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD. The ultimate goal is to support the management of MAFLD and improve patients' quality of life by reducing both morbidity and mortality.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-03; most recent amendment 2026-01-11.
Trial Details
NCT Number NCT07053709
Lead Sponsor Assiut University
Conditions Hyperuricemia and MAFLD
Enrollment 200 participants
Start Date 2026-11-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-13